Cost-utility analysis studies of depression management: A systematic review

被引:49
|
作者
Pirraglia, PA
Rosen, AB
Hermann, RC
Olchanski, NV
Neumann, P
机构
[1] Brown Univ, Sch Med, Rhode Isl Hosp, Div Gen Internal Med, Providence, RI 02903 USA
[2] Harvard Univ, Sch Publ Hlth, Harvard Ctr Risk Anal, Program Econ Evaluat Med Technol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02115 USA
[4] Tufts Univ New England Med Ctr, Hlth Inst, Dept Psychiat, Boston, MA 02111 USA
来源
AMERICAN JOURNAL OF PSYCHIATRY | 2004年 / 161卷 / 12期
关键词
D O I
10.1176/appi.ajp.161.12.2155
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Depression is common, costly, treatable, and a major influence on quality of life. Cost-utility analysis combines costs with quantity and quality of life into a metric that is meaningful for studies of interventions or care strategies and is directly comparable to measures in other such studies. The objectives of this study were to identify published cost-utility analyses of depression screening, pharmacologic treatment, nonpharmacologic therapy, and care management; to summarize the results of these studies in an accessible format; to examine the analytic methods employed; and to identify areas in the depression literature that merit cost-utility analysis. Method: The authors selected articles regarding cost-utility analysis of depression management from the Harvard Center for Risk Analysis Cost-Effectiveness Registry. Characteristics of the publications, including study methods and analysis, were examined. Cost-utility ratios for interventions were arranged in a league table. Results: Of the 539 cost-utility analyses in the registry, nine (1.7%) were of depression management. Methods for determining utilities and the source of the data varied. Markov models or cohort simulations were the most common analytic techniques. Pharmacologic interventions generally had lower costs per quality-adjusted life year than nonpharmacologic interventions. Psychotherapy alone, care management alone, and psychotherapy plus care management all had lower costs per quality-adjusted life year than usual care. Depression screening and treatment appeared to fall within the cost-utility ranges accepted for common nonpsychiatric medical conditions. Conclusions: There is a paucity of literature on cost-utility analysis of depression management. High-quality cost-utility analysis should be considered for further research in depression management.
引用
收藏
页码:2155 / 2162
页数:8
相关论文
共 50 条
  • [1] Echocardiography in the management of stroke: Systematic review and cost-utility analysis.
    Saha, S
    Meenan, RT
    Chou, R
    Swarztrauber, K
    Krages, KP
    O'Keeffe-Rosetti, M
    Mcdonagh, M
    Chan, BK
    Hornbrook, MC
    Helfand, M
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 : 140 - 140
  • [2] Cost-utility analysis in spine care: a systematic review
    Kepler, Christopher K.
    Wilkinson, Sean M.
    Radcliff, Kristen E.
    Vaccaro, Alexander R.
    Anderson, David G.
    Hilibrand, Alan S.
    Albert, Todd J.
    Rihn, Jeffrey A.
    [J]. SPINE JOURNAL, 2012, 12 (08): : 676 - 690
  • [3] The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review
    Sonntag, Michael
    Koenig, Hans-Helmut
    Konnopka, Alexander
    [J]. PHARMACOECONOMICS, 2013, 31 (12) : 1131 - 1154
  • [4] Cost-Utility Analyses of Cognitive-Behavioural Therapy of Depression: A Systematic Review
    Brettschneider, Christian
    Djadran, Helei
    Haerter, Martin
    Loewe, Bernd
    Riedel-Heller, Steffi
    Koenig, Hans-Helmut
    [J]. PSYCHOTHERAPY AND PSYCHOSOMATICS, 2015, 84 (01) : 6 - 21
  • [5] The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review
    Michael Sonntag
    Hans-Helmut König
    Alexander Konnopka
    [J]. PharmacoEconomics, 2013, 31 : 1131 - 1154
  • [6] A SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES IN DIABETES
    Zhong, Y.
    Lin, P. J.
    Winn, A.
    Cohen, J. T.
    Neumann, P. J.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A166 - A166
  • [7] SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES IN ASIA
    Lin, P. J.
    Thorat, T.
    Fang, C. H.
    Neumann, P. J.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A646 - A646
  • [8] Value-based Care in the Management of Spinal Disorders: A Systematic Review of Cost-utility Analysis
    Indrakanti, Santoshi S.
    Weber, Michael H.
    Takemoto, Steven K.
    Hu, Serena S.
    Polly, David
    Berven, Sigurd H.
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2012, 470 (04) : 1106 - 1123
  • [9] Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies
    Kumar, S. Sajith
    Bagepally, Bhavani Shankara
    Sasidharan, Akhil
    [J]. CLINICAL DRUG INVESTIGATION, 2023, 43 (02) : 97 - 108
  • [10] Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies
    S Sajith Kumar
    Bhavani Shankara Bagepally
    Akhil Sasidharan
    [J]. Clinical Drug Investigation, 2023, 43 : 97 - 108